We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+34.12%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$73.8M
AUM Growth
+$28.4M
Cap. Flow
+$17.1M
Cap. Flow %
23.17%
Top 10 Hldgs %
55.69%
Holding
77
New
37
Increased
5
Reduced
25
Closed
2

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$1.64M
2
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$1.49M
3
IMMU
Immunomedics Inc
IMMU
+$1.01M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$713K
5
INSM icon
Insmed
INSM
+$698K

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$870K
2
BIIB icon
Biogen
BIIB
+$320K
3
EXEL icon
Exelixis
EXEL
+$233K
4
IONS icon
Ionis Pharmaceuticals
IONS
+$141K
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$130K

Sector Composition

Rank Sector Weight
1 Healthcare 57.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
51
Nektar Therapeutics
NKTR
$2.41B
$346K 0.47%
687
-195
-22% -$116K
GTHX
52
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$346K 0.47%
+20,844
New +$395K
AMRN
53
Amarin Corp
AMRN
$290M
$345K 0.47%
+832
New +$300K
XNCR icon
54
Xencor
XNCR
$1.47B
$340K 0.46%
+10,935
New +$364K
AGIO icon
55
Agios Pharmaceuticals
AGIO
$2.2B
$324K 0.44%
4,806
-309
-6% -$18K
ACAD icon
56
Acadia Pharmaceuticals
ACAD
$4.35B
$322K 0.44%
11,981
-2,918
-20% -$68.1K
CKPT
57
DELISTED
Checkpoint Therapeutics
CKPT
$322K 0.44%
11,276
– –
SGMO
58
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$320K 0.43%
+33,529
New +$342K
TECH icon
59
Bio-Techne
TECH
$11.2B
$308K 0.42%
6,204
-844
-12% -$38K
CRL icon
60
Charles River Laboratories
CRL
$10.8B
$307K 0.42%
2,112
-553
-21% -$72.7K
IQV icon
61
IQVIA
IQV
$35.6B
$286K 0.39%
1,985
-658
-25% -$87.7K
ALKS icon
62
Alkermes
ALKS
$8.79B
$282K 0.38%
7,722
+117
+2% +$3.86K
CTMX icon
63
CytomX Therapeutics
CTMX
$708M
$272K 0.37%
+25,284
New +$374K
EXEL icon
64
Exelixis
EXEL
$14B
$272K 0.37%
11,440
-10,206
-47% -$233K
GRFS
65
Grifois
GRFS
$5.27B
$263K 0.36%
13,082
-4,094
-24% -$78.2K
KYNB
66
Kyntra Bio
KYNB
$28.5M
$262K 0.36%
193
-75
-28% -$102K
UTHR icon
67
United Therapeutics
UTHR
$26.3B
$258K 0.35%
2,199
-465
-17% -$54.2K
SURF
68
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$253K 0.34%
+53,063
New +$261K
NBIX icon
69
Neurocrine Biosciences
NBIX
$17.7B
$247K 0.33%
2,807
-179
-6% -$15K
GILD icon
70
Gilead Sciences
GILD
$162B
$238K 0.32%
3,667
-951
-21% -$63.2K
AMGN icon
71
Amgen
AMGN
$203B
$236K 0.32%
1,242
-443
-26% -$84.6K
LGND icon
72
Ligand Pharmaceuticals
LGND
$5.96B
$219K 0.3%
+2,797
New +$212K
ACIU icon
73
AC Immune
ACIU
$234M
$201K 0.27%
+39,801
New +$253K
PGEN icon
74
Precigen
PGEN
$1.93B
$170K 0.23%
32,284
+5,175
+19% +$35.9K
SCTL
75
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$67K 0.09%
12,659
– –
1 2
3
4

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q1 2019 Portfolio in Review

As of Q1 2019, Opus Point Partners Management held 77 positions worth $73.8M, up 62% from $45.4M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management deployed $17.1M of net new capital in Q1 2019, opening 37 new positions and adding to 5 existing holdings. Its largest new stake was Bristol-Myers Squibb: 33,000 shares worth $1.57M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 50% a quarter earlier.

On the sell side, the largest reduction was Exelixis, an estimated $233K trimmed.

  • Opus Point Partners Management's largest Q1 2019 buy was Bristol-Myers Squibb: 33,000 shares worth $1.57M.
  • Opus Point Partners Management added most to Direxion Daily S&P Biotech Bull 3X ETF in Q1 2019, an estimated $1.49M increase.
  • Opus Point Partners Management's biggest Q1 2019 reduction was Exelixis, cutting an estimated $233K.
  • Opus Point Partners Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $870K.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $73.8M portfolio in Q1 2019.
  • Opus Point Partners Management opened 37 new positions and closed 2 in Q1 2019.
  • Opus Point Partners Management's portfolio value rose 62% quarter-over-quarter to $73.8M.

Based on Opus Point Partners Management's 13F filing for Q1 2019, filed 15 May 2019.